Ultragenyx Faces Lawsuit Deadline for Investor Losses

Kahn Swick & Foti, LLC reminds investors of April 6 deadline to file lead plaintiff applications in class action against Ultragenyx Pharmaceutical Inc.

Apr. 4, 2026 at 2:32am

Got story updates? Submit your updates here. ›

A photorealistic studio still-life image of a shattered glass vial or beaker, symbolizing the legal and financial challenges facing Ultragenyx Pharmaceutical as it navigates a class action lawsuit from investors.A shattered pharmaceutical vessel reflects the legal and financial uncertainty facing Ultragenyx as it battles a class action lawsuit from investors.New Orleans Today

Kahn Swick & Foti, LLC, a law firm led by former Louisiana Attorney General Charles C. Foti, Jr., is reminding investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. The lawsuit is related to investor losses in excess of $100,000.

Why it matters

This lawsuit represents a significant legal challenge for Ultragenyx, a pharmaceutical company, as it faces potential financial liabilities and reputational damage from the class action. The outcome could impact the company's future operations and financial standing.

The details

The class action lawsuit alleges that Ultragenyx made false and/or misleading statements and/or failed to disclose information pertinent to investors. The company is reportedly evaluating its planned operations and will implement expense reductions in response to the legal action.

  • The deadline for investors to file lead plaintiff applications is April 6, 2026.

The players

Kahn Swick & Foti, LLC

A law firm that is leading the class action lawsuit against Ultragenyx Pharmaceutical Inc.

Charles C. Foti, Jr.

The former Attorney General of Louisiana and a partner at Kahn Swick & Foti, LLC.

Ultragenyx Pharmaceutical Inc.

A pharmaceutical company facing a class action lawsuit related to investor losses.

Got photos? Submit your photos here. ›

What they’re saying

“Kahn Swick & Foti, LLC ('KSF') and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc.”

— Charles C. Foti, Jr., Former Attorney General of Louisiana, Partner at Kahn Swick & Foti, LLC

What’s next

The judge will decide on whether to allow the class action lawsuit to proceed after the April 6, 2026 deadline for investors to file lead plaintiff applications.

The takeaway

This lawsuit highlights the legal risks and potential financial liabilities that pharmaceutical companies can face when investors allege the company made false or misleading statements. The outcome could significantly impact Ultragenyx's future operations and financial standing.